Aurobindo Pharma Ltd.
Fundamentals
- Market cap
- ₹89,483 cr
- P/E
- 25.53×
- ROE
- 10.68%
- Debt / equity
- 0.24
- Div yield
- 0.26%
- 52-week range
- 1016.10 — 1550.90
Aurobindo Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 7 notes on Aurobindo Pharma Ltd.
June 2026
- 19 Jun 26 · 8:25 AM IST Lead Lead · Regulatory · Large cap
Aurobindo gets FTC nod for Lannett, moves closing to June
The US regulator clears a key hurdle for the generics deal announced last July. Aurobindo now expects to close before end of June, ahead of initial guidance.
- 12 Jun 26 · 6:18 PM IST Lead Lead · Large cap
Aurobindo gets second OAI plant in six months
Unit-III in Pashamylaram joins Unit-I on FDA's enforcement track after an inspection with 11 observations. Warning letter or import alert possible.
May 2026
- 22 May 26 · 9:55 AM IST Brief Brief · Concalls · Large cap
Aurobindo sees FY27 margins topping 21% after record ₹33,653 cr revenue year
Management guided for EBITDA margins above 21% in FY27, up from FY26, with Pen-G integration and European scale-up as the main levers. Biosimilars revenue now pushed to 2028.
- 21 May 26 · 10:44 PM IST Brief Brief · Earnings · Large cap
Aurobindo’s FY26 audited results are a formality. Profit growth is 0.6%.
The board approved audited numbers already public via a May press release. Consolidated PAT for the full year rose **0.6%** to **₹35,030 crore**.
- 21 May 26 · 8:49 PM IST Brief Brief · Earnings · Large cap
Aurobindo's TheraNym to build a drug plant for MSD, capex up to $175M
A new greenfield facility for Merck Sharp & Dohme is the sharpest detail in an otherwise routine earnings recap.
- 21 May 26 · 8:47 PM IST Brief Brief · Earnings · Large cap
Aurobindo's FY26 revenue grows 5.6%, profit up 2%
The Indian drugmaker's audited annual results show modest, steady growth. No guidance changes, no surprises.
- 21 May 26 · 7:44 PM IST Brief Brief · Earnings · Large cap
Aurobindo's Q4 profit grew. That's the job.
A routine earnings release. The board signed off on FY26 numbers showing sequential and year-on-year profit gains, with no new guidance.